4564-87-8

Basic information

• Product Name: carbomycin
• Synonyms: carbomycin;3-Methyl-butyric acid 6-{[(Z)-7-acetoxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxo-ethyl)-4,17-dioxa-bicyclo[14.1.0]heptadec-14-en-9-yloxy]-dimethylamino-hydroxy-methyl-tetrahydro-pyran-3-yloxy}-4-hydroxy-2,4-dimethyl-tetrahydro-pyran-3-yl ester;Aids012086;Aids-012086;Magnamycin a;Nsc51001;(12S,13S)-9-Deoxy-12,13-epoxy-12,13-dihydro-9-oxoleucoMycin V 3-Acetate 4B-(3-Methylbutanoate);CarboMycin A
• CAS NO: 4564-87-8
• Molecular Formula: C42H67NO16
• Molecular Weight: 841.982
• Product Categories: Amines;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 4564-87-8.mol
• Article Data: 1

Chemical Properties

• Melting Point: 214°
• Boiling Point: 769.45°C (rough estimate)
• Flash Point: 493.4°C
• Appearance: /
• Density: 1.1761 (rough estimate)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.6220 (estimate)
• PKA: pKb 7.2(at 25℃)
• CAS DataBase Reference: carbomycin(CAS DataBase Reference)
• NIST Chemistry Reference: carbomycin(4564-87-8)
• EPA Substance Registry System: carbomycin(4564-87-8)

Safety Data

• Hazardous Substances Data: 4564-87-8(Hazardous Substances Data)

Usage

Description

Carbomycin is a sixteen-membered-ring macrolide antibiotic complex, similar to Leucomycin and Erythromycin, which is produced by Streptomyces halstedii. It is known for its potent antibacterial properties and has been widely used in the medical field.

Uses

Used in Pharmaceutical Industry:
Carbomycin is used as an antibiotic for treating a variety of bacterial infections. Its broad-spectrum activity makes it effective against both gram-positive and gram-negative bacteria, including Streptococcus, Staphylococcus, and Haemophilus species. It works by inhibiting bacterial protein synthesis, thus stopping the growth and reproduction of the bacteria.
Additionally, carbomycin can be used in combination with other antibiotics to enhance their effectiveness and combat antibiotic-resistant strains. This makes it a valuable asset in the development of new antimicrobial therapies and the fight against drug-resistant infections.

Originator

Magnamycin,Pfizer,US,1953

Manufacturing Process

A selected strain of Streptomyces halstedii was cultivated in an aqueous nutrient medium under aerobic conditions and the resulting broth containing carbomycin antibiotics was filtered. The solutions was extracted twice at pH 6.5 with one-quarter volume of methyl isobutyl ketone. The combined extracts were concentrated to one-tenth volume under vacuum, and the antibiotics were extracted into water adjusted to a pH of about 2 with sulfuric acid. After adjusting the separated aqueous solution to pH 6.5, the antibiotic was extracted into benzene and the solution was concentrated to a small volume. Addition of hexane resulted in the separation of a solid product containing the benzene complexes of carbomycin A and carbomycin B, present in the fermentation broth.

Therapeutic Function

Antibiotic

Safety Profile

Poison by subcutaneous route. Moderately toxic by intravenous and intramuscular routes. When heated to decomposition it emits toxic fumes of NOx.

InChI:InChI=1/C42H67NO16/c1-21(2)16-32(47)57-40-25(6)53-34(20-42(40,8)50)58-37-24(5)54-41(36(49)35(37)43(9)10)59-38-27(14-15-44)17-22(3)28(46)12-13-29-30(56-29)18-23(4)52-33(48)19-31(39(38)51-11)55-26(7)45/h12-13,15,21-25,27,29-31,34-41,49-50H,14,16-20H2,1-11H3/b13-12+/t22-,23-,24?,25?,27+,29?,30+,31-,34?,35?,36?,37?,38+,39+,40?,41?,42?/m1/s1

Relevant articles and documents

Isolation of maridomycins and structure of maridomycin II.

-